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Abstract The role Hsp60 might play in various inflammatory
and autoimmune diseases is under investigation, but little
information exists pertaining to Hashimoto’s thyroiditis
(HT). With the aim to fill this gap, in the present work, we
directed our attention to Hsp60 participation in HT pathogen-
esis. We found Hsp60 levels increased in the blood of HT
patients compared to controls. The chaperonin was
immunolocalized in thyroid tissue specimens from patients
with HT, both in thyrocytes and oncocytes (Hurthle cells) with
higher levels compared to controls (goiter). In oncocytes, we
found Hsp60 not only in the cytoplasm but also on the plasma
membrane, as shown by double immunofluorescence
performed on fine needle aspiration cytology. By bioinformat-
ics, we found regions in the Hsp60 molecule with remarkable
structural similarity with the thyroglobulin (TG) and thyroid
peroxidase (TPO) molecules, which supports the notion that
autoantibodies against TG and TPO are likely to recognize
Hsp60 on the plasma membrane of oncocytes. This was also
supported by data obtained by ELISA, showing that anti-TG
and anti-TPO antibodies cross-react with human recombinant
Hsp60. Antibody-antigen (Hsp60) reaction on the cell surface
could very well mediate thyroid cell damage and destruction,
perpetuating inflammation. Experiments with recombinant
Hsp60 did not show stimulation of cytokine production by
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peripheral blood mononuclear cells from HT patients. All
together, these results led us to hypothesize that Hsp60 may
be an active player in HT pathogenesis via an antibody-
mediated immune mechanism.
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Introduction
Hashimoto's thyroiditis (HT) is the commonest cause of pri-
mary hypothyroidism in humans (Vanderpump and Tunbridge
2002). It is an autoimmune disease characterized by a
prolonged autoimmune response against thyroid tissue that
alters significantly the morphology of the gland (Ahmed et al.
2012). Classic histological features of HT include small,
degenerated follicles, oncocytic (Hurthle cell) metaplasia,
and lymphoid infiltrates arranged in follicles (Lorini et al.
2003; Ahmed et al. 2012). Clinical features include increased
levels of antibodies to thyroglobulin (TG) and thyroid perox-
idase (TPO), two proteins localized within the thyroid gland
cells (Lorini et al. 2003). It has been postulated that, as a result
of interaction of the antibodies with TG and TPO, inflamma-
tion develops in the thyroid gland, the gland is destroyed, and
the patient ultimately is rendered hypothyroid (Ahmed et al.
2012). However, since TG and TPO are localized inside the
cells, other mechanisms must also be implicated in cell lysis
and gland destruction. These latter mechanisms are still largely
unknown.
Numerous molecular chaperones have been identified at
sites of autoimmune diseases such as rheumatoid arthritis
(Yokota et al. 2000; Kotlarz et al. 2013), systemic lupus
erythematosus (Yokota et al. 2000), and other autoimmune
conditions (Pockley et al. 2008). One of these chaperones, the
chaperonin Hsp60, has been found elevated in autoimmune
and chronic inflammatory diseases, such as rheumatoid arthri-
tis (Yokota et al. 2000), Crohn's disease (Rodolico et al. 2010),
ulcerative colitis (UC) (Rodolico et al. 2010; Tomasello et al.
2011a, b), periodontitis (Rizzo et al. 2012), and chronic ob-
structive pulmonary disease (COPD) (Cappello et al. 2011).
Furthermore, the data suggested that Hsp60 is likely involved
in the maintenance of inflammation in UC and COPD by
activation of, respectively, macrophages and neutrophils
(Tomasello et al. 2011a, b; Cappello et al. 2011). In contrast,
very little is known about the involvement of Hsp60 in HT
pathogenesis.
Hsp60 is classically described as an intramitochondrial
protein involved in assisting the correct folding of other mi-
tochondrial client proteins (Hartl 1991; Pace et al. 2013).
However, during the pathogenetic steps of a number of
conditions, Hsp60 accumulates in the cytosol (Cappello
et al. 2008), reach the plasma membrane (Cechetto et al.
2000; Campanella et al. 2012), and is secreted via the lipid
rafts–exosomal pathways (Gupta and Knowlton 2007;
Merendino et al. 2010; Campanella et al. 2012). When in the
extracellular environment, Hsp60 may interact with receptors
present on immune cells (Osterloh et al. 2007; Zanin-Zhorov
et al. 2006; Xie et al. 2010) and also reach the bloodstream
acting—analogously to other molecular chaperones—as a
“chaperokine” at distant sites (Asea 2003; Gazali 2012).
Hsp60 may also elicit production of autoantibodies against
itself and, thereby, induce an autoimmune response in several
tissues in which Hsp60 occurs (Pockley et al. 1999; Rea et al.
2001; Cappello et al. 2009). Therefore, in the last years,
Hsp60 is gaining attention as a key player in a number of
chronic inflammatory and autoimmune diseases.
In this work, we investigated the levels of Hsp60 in the
blood of HT patients and determined the distribution of the
chaperonin in the thyroid gland of subjects affected by HT.
Finally, we evaluated its structural similarities with TG and
TPO, which might lead to immune cross-reactivity and, thus,
to thyroid lesions at the sites in which the chaperonin locali-
zation in plasma membrane occurs.
Materials and methods
Patients’ recruitment, clinical and laboratory analyses,
and fine needle aspiration
Forty-five patients, 28 male and 17 female of ages between 19
and 44 years (mean, 33) at their first diagnosis of HT, were
recruited at the Department of Internal Medicine and Medical
Specialties of the University of Palermo, Italy. A blood sample
was obtained from each subject for routine hematoclinical
analyses, including determinations of free triiothyronine
(FT3), free thyroxine (FT4), thyroid stimulating hormone
(TSH), and anti-thyroid peroxidase (anti-TPO), and anti-
thyroglobulin (anti-TG) antibodies. Both hormones and anti-
bodies were measured using a chemiluminescence
immunometric assay (Immulite 2000, Siemens Medical
Solutions Diagnostics, Los Angeles, CA, USA), with the
following reference ranges: FT3=1.8–4.2 pg/mL (conversion
factor: pg/mL×1.536=pmol/L); FT4=0.8–1.9 ng/dL (conver-
sion factor: ng/dL×12.87=pmol/L); TSH=0.4–4 μIU/mL
(analytical sensitivity=0.004 μIU/mL); anti-TPO=0–35 IU/
mL; and anti-TG=0–40 IU/mL. Moreover, the thyroid gland
of each subject was submitted to grayscale ultrasonography
(GSUS) to determine its volume using an ultrasound mobile
system Logiq P5 (General Electric Medical Systems,
Milwaukee, WI, USA) equipped with a wide bandwidth
(range, 7–12 MHz) transducer. GSUS was performed at
12 MHz. For each patient included in the study, we recorded
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thyroid volume by ultrasonography (expressed in milliliters)
calculating the ellipsoid formula (longitudinal diameter×
transverse diameter×antero-posterior diameter×π /6) applied
to each lobe. In addition, ten subjects (five male and five
female) selected randomly from the entire population studied
(45 subjects) were submitted to fine needle aspiration (FNA)
of thyroid for immunocytologic studies (see below). From the
latter subjects, a supplementary blood sample was also col-
lected for flow cytometry experiments (see below).
Determination of circulating levels of Hsp60 by ELISA
ELISA was performed as previously described (Rizzo et al.
2012) using a commercial Hsp60 (human) enzyme immuno-
assay (EIA) kit (ADI EKS 600 ELISA kit from Enzo Life
Sciences, Inc., Farmingdale, NY, USA). We performed a
quantitative comparison of Hsp60 levels in plasma of the
patients with HT with those of 45 age-matched normal con-
trols randomly selected from our files. Awhole blood sample
from each subject was collected in EDTA-treated tubes. After
a centrifugation at 2,000×g for 10 min, plasma was collected,
aliquoted, and stored at −20 °C until use. The Hsp60 standard
was diluted in sample diluent to generate a standard curve
with six points, ranging from 3.125 to 100 ng/mL, and sample
diluent alone was used as 0 (zero) standard. First, 100 μL of
prepared standards and undiluted plasma was added in dupli-
cate to wells of the immunoassay plate precoated with mouse
monoclonal antibody specific for Hsp60 and incubated at
23 °C for 1 h. The primary and the secondary antibodies were
diluted according to the manufacturer's instructions. Then,
100 μL of diluted anti-Hsp60 goat polyclonal antibody was
added to each well and incubated at 23 °C for 1 h. After
washing, 100 μL of diluted horse radish peroxidase-
conjugate anti-goat IgG was added to the plate and incubated
at 23 °C for 30 min followed by 100 μL of 3,3′,5,5′-
tetramethylbenzidine substrate for 15 min in the dark.
Finally, 100 μL of Stop Solution was added, and absorbance
was measured at 450 nm in a microplate photometric reader
(DV990BV4, GDV, Milan, Italy). Sample concentration was
calculated by interpolating the sample concentrations in the
standard curve. The sensitivity of the human Hsp60, EIA kit
was determined to be 3.125 ng/mL. Human Hsp60 EIA kit is
specific for Hsp60 and the Hsp60 ELISA has been certified
for the detection of human Hsp60.
Collection of histological specimens
Surgical specimens from patients that underwent thyroid gland
removal were retrospectively obtained from the Pathologic
Anatomy Unit of the Section of Human Pathology of the
University of Palermo, Italy. Ten cases of HT and 10 cases of
goiter, as controls, were studied. All tissues were formalin-
fixed and paraffin embedded. Five-micrometer sections were
obtained from the blocks for the immunohistochemical and
immunofluorescence studies.
Immunomorphological analyses: immunohistochemistry
and immunofluorescence
Immunohistochemistry was performed as previously de-
scribed (Tomasello et al. 2011a, b) on 5-μm sections of HT
and goiter tissues, using Histostain-Pluss IHC detection Kit
(Histostain-plus Kit 3rd Gen IHC Detection Kit, Invitrogen
Corporation, catalogue no. 85-9073, Camarillo, CA, USA),
and a primary antibody against human Hsp60 (mouse anti-
Hsp60 monoclonal antibody, Sigma, St. Louis,MO, catalogue
no. H4149, dilution 1:400). Appropriate positive controls, and
nonimmune serum for negative controls, were run concurrent-
ly. Nuclear counterstaining was done using hematoxylin
(DAKO, Carpinteria, CA, USA). Three independent ob-
servers (FR, FC, and DC) examined the specimens in a blind,
code-marked approach and performed a quantitative analysis
to determine the percentage of cells positive for Hsp60 in
thyrocytes and oncocytes. All the observations were made at
a magnification of ×400, and the means of triplicate counts
were used for statistical analyses.
Double immunofluorescence tests were performed to assess
the colocalization of Hsp60 and TG in 5-μm sections of HTand
goiter, as previously described (Serradifalco et al. 2011).
Briefly, after dewaxing in xylene, rehydration in ethanol, and
washing in phosphate-buffered solution (PBS), sections were
incubated with unmasking solution (tri-sodium citrate 10 mM,
0.05% Tween 20) for 10 min at 58 °C and treated with blocking
solution (3 % albumin bovine serum in PBS) for 30 min at
23 °C. Then, the sections were incubated with the first primary
antibody (rabbit polyclonal antihuman HSP60, Clone H300,
Santa Cruz Biotechnology, Dallas, USA, catalogue no. sc-
13966) diluted 1:100, overnight at 4 °C. The day after, some
sections were incubated with the second primary antibody
(Mouse Monoclonal anti-Thyroglobulin, Clone 2H11/6E1,
Genemed Biotechnologies, South San Francisco, CA, USA,
catalogue no. 61-0064-5) diluted 1:100, overnight at 4 °C. After
washing twice in PBS all sections were incubated with fluores-
cent secondary antibodies such us rabbit IgG antibody conju-
gated with Texas Red (diluted 1:200; Gene Tex Inc, Irvine,
USA) and mouse IgG antibody conjugated with fluorescein
isothiocyanate (FITC; diluted 1:200; Sigma-Aldrich, Milan,
Italy) respectively.
Double immunofluorescence tests were also performed to
assess the colocalization of Hsp60 and integrin (a plasma
membrane marker) in cytologic preparations obtained after
FNA by thin prep, as described by Tulecke and Wang (2004).
The specimens were incubated with unmasking solution (tri-
sodium citrate 10 mM, 0.05% Tween 20) for 10 min at
23 °C, treated with blocking solution and incubated
with the first primary antibody against Hsp60 diluted 1:100
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(rabbit polyclonal anti-Hsp60, Clone H300, Santa Cruz
Biotechnology) overnight at 4 °C. Subsequently, the slideswere
incubated with the second primary antibody against integrin
diluted 1:100 (goat polyclonal anti-integrin β3, clone C20,
Santa Cruz Biotechnology, catalogue no. sc6626) overnight at
4 °C. After washing twice in PBS, all slides were incubated
with fluorescent secondary antibodies (rabbit IgG antibody
conjugated with Texas Red, Gene Tex Inc, dilution 1:200;
FITC-conjugated donkey antigoat secondary antibody, Gene
Tex Inc., dilution 1:200) for 1 h each at 23 °C. The nuclei were
counterstained with Hoechst (Sigma-Aldrich, Inc, Milan, Italy)
for 15 min at 23 °C. Finally, all slides were mounted with
cover slips using a drop of PBS, and readings and imaging
were immediately performed with a Leica DM5000 upright
fluorescence microscope (Leica Microsystems, Heidelberg,
Germany).
Isolation and stimulation of peripheral blood mononuclear
cells
Peripheral blood mononuclear cells (PBMC) were isolated
from fresh heparinized blood from healthy and HT subjects
(the same group studied with FNA, see above) by density
gradient centrifugation with Fycoll-Hypaque (Pancoll, Pan
Biotech). After washing, the cells were resuspended in
RPMI 1640 medium with 10 % heat-inactivated fetal calf
serum and supplemented with 2 mM glutamine, 50 U/ml
penicillin, and 50 mg/streptomycin. Cell culture reagents
were purchased from GIBCO BRL LIFE Technologies
(Invitrogen, Italy). Finally, PMBCs (2×105 cells) were cul-
tured in six-well tissue-culture plates at 37 °C in a humidified,
5 % CO2, incubator and stimulated with three different doses
(1, 5, and 10 μg/ml) of recombinant human Hsp60 (rhHsp60)
(Vinci Biochem, Milan, Italy) for various times (8, 24, and
48 h). To verify endotoxin contamination of the commercial
rhHsp60, we also determined the amount of endotoxin by the
quantitative chromogenic Limulus amebocyte lysate assay
(QCL-1000; BioWhittaker, Walkersville, MD, USA)
according to the manufacturer's instructions, as described
(Bethke et al. 2002). The endotoxin concentration was calcu-
lated as EU per milliliter. The endotoxin concentration was
<0.5 EU/μg.
Detection of cytokines in conditioned medium
After incubation, the supernatants were collected from each
plate to measure inflammatory cytokine production after
rhHsp60 stimulation. We used the inflammatory human cyto-
kine cytometric bead array (BD™ CBA Human Th1/Th2
Cytokine Kit II, BD Biosciences) to measure interleukin
(IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF), and
interferon gamma (IFN-γ) following the manufacturer's di-
rections (Collins et al. 1998). The fluorescence was measured
on a FACSCalibur (BD Biosciences) analyzed with FCAP
Array software (BD Biosciences).
Bioinformatics evaluation of regional similarity between
Hsp60 and, respectively, TG and TPO
The amino-acid sequences of Hsp60, TG, and TPO were
obtained from the PubMed website (http://www.ncbi.nlm.
nih.gov/genbank/) using, respectively, the following access
numbers: Hsp60, Homo sapiens GenBank, accession number
NM_002156; thyroglobulin, Homo sapiens GenBank,
accession number CAA29104; and thyroid peroxidase,
Homo sapiens GenBank, accession number AAA61217.
Fig. 1 Plots of the correlation analyses between the plasma levels of
Hsp60 and those of the anti-TPO and anti-TG antibodies, and thyroid
volume. The Hsp60 plasma levels positively correlated with those of anti-
TPO antibodies (a r=0.484, p=0.0008 and anti-TG antibodies (b r=
0.379, p =0.0103) with thyroid volume (c r=0.357, p=0.0328)
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Sequence comparisons were performed, as described (Marino
Gammazza et al. 2012), using the open access SIM software
(http://expasy.org/tools/sim-prot.html). The three-dimensional
model of the Hsp60 monomer was obtained using the 3D-
JIGSAW software (http://bmm.cancerresearchuk.org) and
visualized by PyMol (http://www.pymol.org). All software
used are open access.
Determination of Hsp60 cross-reactivity with TG and TPO
by ELISA
Microplates were coated with 1, 5, or 10 μg/mL (50 μL/well)
of rhHsp60 (Vinci Biochem, Italy) by overnight incubation at
4 °C. The wells were rinsed with 100 μL of PBS three times
and blocked with 200 μL/well of blocking buffer (3% BSA in
PBS) for 1 h at 23 °C. After blocking, the wells were filled
with primary antibodies diluted 1:1,000 in PBS for 1 h at
23 °C.We used the primary antibodies we had chosen because
they recognize the epitopes of the proteins that bioinformatics
analyses showed to have high similarity with Hsp60, as fol-
lows: (1) mouse monoclonal antihuman TG (Santa Cruz
Biotechnology, Dallas, USA, catalogue no. sc7836) and (2)
mouse monoclonal antihuman TPO, (Abcam, Cambridge,
UK, catalogue no. ab76935). Morevoer, we used a mouse
monoclonal antihuman Hsp60 antibody (Sigma, St. Louis,
MO, catalogue no. H4149) as positive control and a
goat polyclonal anti-integrin αM antibody (Santa Cruz
Biotechnology, Dallas, TX, USA, catalogue no. sc6614) as
negative control. Wells without primary antibodies were also
prepared and incubated with PBS. After incubation, all the
wells were washed extensively with PBS, and the secondary
antibodies were added at 1:3000 dilution for 1 h at 23 °C, as
follows: antimouse horseradish peroxidase-linked whole an-
tibody (GE Healthcare, Little Chalfont, UK) and antigoat
horseradish peroxidase-linked whole antibody (Sigma-
Aldrich Italy, Milan, Italy). After washing, 100 μL of
o -phenylenediamine dihydrochloride (DAKO) was added
to each well and incubated for 30 min at 23 °C in the dark.
The reaction was terminated with the addition of 100 μL of
0.5 mol/L sulfuric acid, and absorbance values were read at
492 nm, using an ELISA plate reader (DV990BV4, GDV,
Milan, Italy).
Statistical analyses
Statistical analyses were performed using Statview® 5.0 (SAS
Institute Inc., Cary, NC, USA). Correlation analyses were
performed using the Spearman rank correlation method.
Multivariate analysis was performed in order to assess poten-
tial independent associations between anti-TPO and anti-TG
antibody levels, as well as the thyroid volume and the thyroid
hormonal pattern (levels of FT3, FT4, and TSH).
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Fig. 2 Immunohistochemical
demonstration of Hsp60 in
thyroid tissues. Hsp60 was
abundantly present only in
thyroid specimens from HT (a)
while in goiter it was scarce or
absent (b). Positivity for Hsp60
was localized both to small
and degenerated follicles (c)
and to oncocytic islets (d).
Bars: 100 μm
Results
Hsp60 levels and correlation with anatomoclinical parameters
in subjects with HT
Hsp60 levels in plasma of HT subjects were undetectable in two
of 45 subjects and ranged between 3.125 and 64.218 ng/mL
(mean, 16.788; SD, 11.082) in the others, including two very
high values; by contrast, in normal subjects, Hsp60 was
undetectable in 12 of 45 subjects and ranged between 3.125
and 24.397 ng/mL (mean, 7.586; SD, 4.043) in the others. The
difference between Hsp60 levels in HT versus normal subjects
was significant (p<0.02).
As shown in Fig. 1, Hsp60 plasma levels positively corre-
lated with the levels of antibodies anti-TPO (r =0.484, p =
0.0008; Fig. 1a) and anti-TG (r =0.379, p =0.0103; Fig. 1b),
and with the thyroid volume (r =0.357, p =0.0328; Fig. 1c).
These associations were independent of the thyroid hormonal
pattern, as demonstrated by multivariate analysis (data not
shown). We adjusted the association between plasma Hsp60
levels and anti-TPO and anti-TG antibody levels and the
thyroid volume for FT3, FT4, and TSH, and we found that
the Hsp60 plasma levels remained significantly associated
with anti-TPO (p =0.0006) and anti-TG (p =0.0084) anti-
body levels and with thyroid volume (p =0.0323).
Immunohistochemistry for Hsp60 in HTcompared with goiter
specimens
Immunohistochemistry showed that Hsp60 was abundantly
present in specimens from HT but not in those from goiter
(Fig. 2). Positivity for Hsp60was localized in thyrocytes of small
and degenerated follicles (Fig. 2a, c) and in oncocytic metaplasia
areas (Fig. 2b). By contrast, thyrocytes from goiter were nega-
tive, or scarcely positive, for Hsp60 (Fig. 2b).
Double immunofluorescence for Hsp60 and TG in HT
compared with goiter specimens
Double immunofluorescence experiments performed on tis-
sue sections revealed that in HT a number of cells showed
double positivity for Hsp60 and TG, while others showed only
Fig. 3 Double
immunofluorescence for Hsp60,
thyroglobulin, and integrin in
thyroid tissues and cells. A
number of cells in HT specimens
(a) showed single staining for
Hsp60 (green) or thyroglobulin
(red), while others presented a
double positivity (orange). Some
of the latter are indicated by
arrows . In contrast, goiter tissue
cells (b) were positive only for
thyroglobulin (red). Double
immunofluorescence for integrin
(green) and Hsp60 (red) in
cytological smears obtained by
fine needle aspiration from HT
thyroids showed Hsp60 positivity
in both cytosol and plasma
membrane (arrows) in oncocytes
(c), but not in thyrocytes (d);
in the latter, Hsp60 occurred
only inside cells. Bars: 100 μm
(a , b) and 10 μm (c , d)
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a single staining (Fig. 3a). Double staining positivity indicated
that Hsp60 was present in thyrocytes (also positive for TG),
although not all thyrocytes were also positive for Hsp60.
Single staining positivity for Hsp60 indicated that this mole-
cule was present also in other cells, most of which had the
characteristic features of oncocytes. Hence, these experiments
suggest that not only thyrocytes but also oncocytes are posi-
tive for Hsp60 in HT specimens. In goiter tissues, cells were
positive only for TG. (Fig. 3b).
Double immunofluorescence for Hsp60 and integrin in HT
cytologic smears
Double immunofluorescence experiments for integrin and
Hsp60 in cells carried out in cytologic smears (ThinPreps)
obtained by FNA from thyroids of patients with HT showed
Hsp60 positivity both in cytosol and in plasma membrane in
large size, round cells with large nucleus, all characteristic of
oncocytes (Fig. 3c; arrows), but not in cells with a follicular
morphology, i.e., with features of thyrocytes (Fig. 3d).
Tests for establishing if Hsp60 would stimulate PBMC
from HT patients to produce cytokines
Since we found that Hsp60 levels in HT tend to be higher than
in normal subjects and considering that the chaperonin is
believed to stimulate cytokine release, we decided to compare
levels of cytokines (IL-2, IL-4, IL-6, IL-10, TNF, and IFN-γ)
secreted by PBMC obtained from either HT patients or
healthy controls. The results would provide insights into
whether or not Hsp60 has a proinflammatory role, i.e., acting
as chaperokine, in HT. PBMC were either treated with
hrHsp60 or left untreated. Cytokine levels did not vary signif-
icantly in any of the observed conditions (data not shown). In
summary, these data suggest that Hsp60 did not stimulate
cytokine production in PBMC from HT patients or normal
subjects.
Bioinformatics: primary structure comparison between Hsp60
and TG or TPO
Since it is known that Hsp60 has a high degree of sequence
similarity with other human proteins (Jones et al. 1993;
Marino Gammazza et al. 2012), we performed bioinformatics
comparative analyses of amino-acid sequences between
Hsp60 and, either, TG or TPO. These analyses showed a high
similarity between Hsp60 and both these thyroid-specific
molecules (Table 1). The alignment of the amino-acid se-
quences of Hsp60 and TPO revealed seven epitopes with a
percentage of identity between 50 and 66.7. Likewise, the
alignment of the amino-acid sequences of Hsp60 and TPO
showed five homologous epitopes with identity percentage
between 58.3 and 80. These epitopes were distributed all
along the amino-acid sequence (Fig. 4).
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Table 1 Regions of similarity
between Hsp60 and either thyro-
globulin or thyroid peroxidase
amino-acid sequences (all human)
revealed by the SIM alignment
a See also Fig. 4
Proteins compared Amino-acid region Sequencea Percentage of identities
Hsp60 vs. thyroglobulin 357–365 LLKGKGDKA 66.7
171–179 LLHGVGDKS
244–253 VLLSEKKISS 60
1982–1991 VPMSEKSISN
531–539 DAAGVASLL 55.6
1014–1022 DSAGASALL
239–247 FQDAYVLLS 55.6
214–222 FPDAFVTFS
304–314 GFGDNRKNQLK 54.5
2008–2018 GFGFLNVSQLK
408–415 GTSDVEVN 50
2049–2056 GSPDIEVH
32–341 FGADARALML 50
2373–2382 FGGDPRRVSL
Hsp60 vs. thyroid peroxidase 322–326 GAVFG 80
302–307 GALFG
439–447 GGGCALLRC 66.7
715–723 GGGTPELRC
508–517 GDFVNMVEKG 60
751–760 GDFVHCEESG
388–399 EKLNERLAKLSD 58.3
558–569 EELTERLFVLSN
481–487 KNAGVEG 57.1
917–923 ESAGMEG
Determination of cross-reactivity between Hsp60 andTG
or TPO by ELISA tests
The bioinformatics results described in the preceding section
predicted cross-reactivity of Hsp60 with TG and with TPO.
This hypothesis was further tested by determining if anti-TG
and anti-TPO antibodies crossreact with Hsp60, using ELISA.
The results confirmed the prediction (Fig. 5).
Discussion
Molecular chaperones are a class of proteins with various
fundamental roles in cell and tissue physiology and in response
to a variety of stressors (Henderson and Pockley 2010;
Macario et al. 2013). Many “chaperones” are also “heat shock
proteins” (Hsps), although not all Hsps are chaperones. Since
they are important in many physiologic processes, a number of
diseases in which chaperone functions are impaired, the
chaperonopathies, have been described (Macario et al. 2013).
From a pathogenetic point of view, chaperonopathies have
been classified in three groups: by defect, for instance due to
chaperone gene mutation, e.g., the hereditary spastic paraple-
gia 13 (Hansen et al. 2002); by excess, due to chaperone gene
overexpression, i.e., COPD (Cappello et al. 2011); and by
mistake, in which chaperones are apparently normal but are
working to the advantage of the disease rather that than to the
host organism, e.g., some forms of tumors (Rappa et al. 2012).
Among chaperonopathies by mistake may be included some
forms of autoimmune diseases in which a supposedly normal
chaperone acts as an autoantigen (Macario et al. 2013).
In this study, we found that Hsp60 levels are increased in
over one third of HT patients compared to controls in plasma
and in all patients studied in thyroid tissue. Moreover, Hsp60
localized to thyroid tissues, both in thyrocytes and oncocytes.
In the latter cells, Hsp60 was present not only in the cytoplasm
but also in the plasma membrane. Since we found regions of
remarkable structural similarity between Hsp60, TG, and
TPO, we postulated that autoantibodies against TG and TPO
are likely to recognize Hsp60 on the plasma membrane of
oncocytes and, thereby, mediate their destruction, perpetuat-
ing inflammation. Data from the literature indicate that even a
very small sequence segment (e.g., two or three amino acids)
(Jorgensen et al. 1992; Singh et al. 2013), and epitopes with
<50 % similarity (Frankild et al. 2008), can induce cross-
reactivity by, both, humoral and innate immune system
Fig. 4 Three-dimensional model of the human Hsp60 showing the amino-
acid sequences (potential crossreactive immunogenic/antigenic epitopes;
various colors) it shares with thyroid specific molecules. a Shared se-
quences between Hsp60 and thyroglobulin (TG); the arrow indicates the
epitope with the highest similarity (66,7 % identities). b Shared sequences
between Hsp60 and thyroid peroxidase (TPO); the epitopes with the
highest (80 % identities) and second highest (66.7 % identities) similarities
are indicated by an arrow and an arrowhead , respectively. See also Table 1
Fig. 5 Hsp60 cross-reactivity
with TG and TPO. ELISA tests
with various concentrations (1, 5,
and 10 μg/ml) of rhHsp60 and
antibodies anti-TG, anti-TPO,
anti-Hsp60 (positive control), and
anti-integrin αM (negative
control) show that both anti-TG
and anti-TPO antibodies are able
to recognise rhHsp60
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activation. It is therefore likely that, as postulated above,
plasma membrane Hsp60 may be an antigen for autoanti-
bodies that might be able to recognize also TG and/or TPO
considering the high percentage of similarity of their shared
epitopes. We confirmed the immunological cross-reactivity of
anti-TG and anti-TPO antibodies with human Hsp60 by
ELISA tests. All these observations indicate that Hsp60 could
have an important role in maintaining autoimmunity in HT
subjects, thus contributing to disease progression.
Hsp60 could also have a role in thyroid pathology by
inducing the production of inflammatory cytokines in inflam-
matory cells infiltrating the thyroid. Although our data do not
support this mechanism, it cannot be excluded. Our results
with PBMC stimulated with preparations of rhHsp60 did not
show cytokine production regardless of the origin of the
PBMC, healthy individuals or HT patients. Nevertheless, it
cannot be ruled out that autologous Hsp60, or even other
Hsp60 preparations, recombinant or otherwise, different from
the one we used, would have had a different effect. This road
remains open for investigation.
We found only a few reports on the involvement of
chaperones/Hsps in HT pathogenesis. Bougacha-Elleuch
et al. (2004) examined single and haplotypic genetic varia-
tions of a number of genes, including Hsp70, but they did not
find any such variations. Heufelder et al. (1992) demonstrated
the expression of Hsp72 in the thyroid gland from patients
with HT. Misaki et al. (1994) suggested that aberrantly
expressed Hsp72 may activate part of the thyroid-infiltrating
lymphocytes and thereby aggravate autoimmune processes.
A similarity between human Hsp60 and 19 known
autoantigens, including TG, has been described in the past
(Jones et al. 1993). Hence, Hsp60 has been postulated to be
involved in a number of autoimmune diseases, including HT.
However, to the best of our knowledge, only one paper dealt
with the role of Hsp60 in HT pathogenesis: Kotani et al.
(1996) showed increased Hsp60 levels in HT follicular cells
compared to controls. Interestingly, no increment was found
of anti-Hsp60 antibodies in HT patients, compared to normal
subjects. These were the data available in the literature, but
they alone seemed us insufficient to postulate a role of Hsp60
in HT pathogenesis. Indeed, Hsp60 may increase in HT tissue
as a physiologic response to a number of pericellular stressors,
as those present during an inflammation.
Also noteworthy are the facts that one region of sequence
similarity between TG and Hsp60 was identified many years
ago (Jones et al. 1993) and that modern bioinformatics tech-
niques allowed us now to identify a greater number of se-
quence similarity regions not only between Hsp60 and TG but
also between Hsp60 and TPO, which—to the best of our
knowledge—were never described before.
These data, combined with the correlation between Hsp60
and both anti-TG and anti-TPO antibody levels in blood of HT
patients, with the presence of Hsp60 in the plasma membrane
of oncocytes, and with the cross-reactivity between Hsp60
andTG and TPO, led us to hypothesize that Hsp60 plays a
determinant role in HT pathogenesis by being involved in the
autoimmune destruction of the gland. However, some ques-
tions are still unanswered: Is part of the Hsp60 molecule
expressed on the cell surface? If this is so, which epitope(s)
are expressed on the surface and are available for antibody
binding? Our findings encourage research in this direction.
In conclusion, this work shows for the first time that: (1)
Hsp60 levels in thyroid tissue and the blood of HTsubjects are
increased compared to controls; (2) Hsp60 is expressed both
in thyrocytes and oncocytic metaplasia cells; in the latter,
Hsp60 is present inside the cell and also at the plasma mem-
brane level; (3) Hsp60 shares structural homology with TG
and TPO over various segments of their amino-acid se-
quences, which constitute potential immunological cross-
reactive epitopes; (4) Hsp60 blood levels tend to correlate
with those of anti-TG and anti-TPO antibodies in HT patients;
(5) rhHsp60 did not induce increment of cytokine (i.e., IL-2,
IL-4 , IL-6, IL-10,TNF, and IFN-γ) production by PBMC in
HT subjects, under the conditions tested; and (6) antibodies
anti-TG and anti-TPO are able to recognize Hsp60. These data
considered together lead us to postulate, as a working hypoth-
esis, that Hsp60 is an active player in HT pathogenesis, via an
antibody-mediated immune mechanism.
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